Indian corporates report mixed Q2 FY27 earnings, with BSE and Apollo Hospitals posting strong gains while Biocon and Zydus Lifesciences see profit declines
Quarterly results released on 4 November 2026 show a range of outcomes: BSE and Apollo Hospitals posted double-digit profit growth, whereas Biocon and Zydus Lifesciences reported sharp drops in net profit.
Several large-cap Indian companies released their second-quarter FY27 earnings on 4 November 2026. BSE Ltd. posted a 44.9% year-on-year rise in consolidated net profit to ₹809.15 crore, with revenue from operations up 34.1% to ₹1,432.66 crore. Apollo Hospitals Enterprise Ltd. reported a 32% increase in consolidated net profit to ₹630 crore, driven by a 23% rise in revenue to ₹7,615 crore.
In contrast, Biocon Ltd. saw its consolidated net profit fall 57.3% to ₹56.7 crore, while total income grew to ₹4,423.4 crore. Zydus Lifesciences Ltd. posted a 61.8% decline in standalone profit to ₹714.5 crore, down from ₹1,156.6 crore a year earlier.
Other notable results included a 32.5% profit jump for Aurobindo Pharma to ₹1,124 crore on 24% revenue growth, a 36% profit rise for NHPC to ₹1,657.57 crore, and a 46% profit increase for Century Plyboards to ₹103.63 crore. Exide Industries reported a 75% surge in profit to ₹386.45 crore, and Power Finance Corporation’s profit rose 12% to ₹4,986.71 crore.
Several firms also announced strategic moves. FSN E-Commerce Ventures (Nykaa) disclosed a 36% increase in standalone profit to ₹16.71 crore and approved an 82% acquisition of Simply Nam for up to ₹33 crore. Sundaram Finance’s managing director highlighted a constructive outlook for the second half of the fiscal year, emphasizing growth and asset-quality focus.
The market reacted with mixed movements: shares of SBI, Bajaj Finserv, Emcure Pharma and Awfis Space rose, while MCX and Bata India fell. The Sensex closed up 0.50% at 77,301.40 and the Nifty 50 gained 0.63% to 23,960.60.